STOCKHOLM, Sweden, June 18, 2003 (PRIMEZONE) -- Active Biotech (Other OTC:ACTBF) today published new data about the development of its SAIK-MS substance for is a Swedish biotechnology company focusing on research and development of pharmaceuticals. Active Biotech has a strong R&D portfolio with pipeline projects in the areas of autoimmune/inflammatory diseases and cancer. The company's pharmaceutical development is based on an in-depth knowledge in immunology.
Active Biotech is currently discussing partnership agreements for a number of projects in clinical development.
The company's primary focus is a novel oral immunomodulatory drug (SAIK-MS), presently in late phase II clinical development for the treatment of multiple sclerosis (final report Q4, 2003).
Collaboration discussions are also ongoing in relation to a novel concept for immunotherapy of cancer (TTS), a project also in phase II clinical development (final report Q4, 2003), as well as for an oral drug (TASQ) designed for the treatment of prostate cancer.
Meet representatives from Active Biotech at the BIO2003 Annual Convention, June 22-25 at the Swedish Pavilion, booth#835.
Active Biotech AB (publ)
For further information about Active Biotech visit www.activebiotech.com.